AstraZeneca is a global, science-led biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. Headquartered in Cambridge, United Kingdom, it was formed in 1999 through the merger of Astra AB (Sweden) and Zeneca Group (UK). The company is listed on the London Stock Exchange and is a constituent of the FTSE 100 index.
AstraZeneca’s portfolio and pipeline focus on oncology; cardiovascular, renal and metabolism; respiratory and immunology; and rare diseases (through Alexion, acquired in 2021). It operates an international network of R&D centers and manufacturing sites that produce small‑molecule active pharmaceutical ingredients and finished dosage forms, as well as biologics such as monoclonal antibodies and other protein therapeutics.
For the chemical and manufacturing value chain, AstraZeneca undertakes large-scale process development, API synthesis, formulation, sterile fill‑finish, and packaging, supported by a global supply network and external manufacturing partnerships.